Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: mollee p. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R. Gandhi MK, et al. Among authors: mollee p. Clin Cancer Res. 2006 Jan 15;12(2):460-4. doi: 10.1158/1078-0432.CCR-05-2008. Clin Cancer Res. 2006. PMID: 16428487
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM. Talaulikar D, et al. Among authors: mollee p. Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311. Intern Med J. 2017. PMID: 28076910
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A. Lee OL, et al. Among authors: mollee p. Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502. Intern Med J. 2017. PMID: 28782211
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P. Scott A, et al. Among authors: mollee p. Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12. Leuk Lymphoma. 2018. PMID: 29022836 No abstract available.
Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.
Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY. Chin CK, et al. Among authors: mollee p. Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676487 Free article. Clinical Trial. No abstract available.
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK. Tobin JWD, et al. Among authors: mollee p. J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28. J Clin Oncol. 2019. PMID: 31461379 Free PMC article.
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.
Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H, Chan H, Juneja S, Harvey Y, Nath L, Hissaria P, Prince HM, Wordsworth H, Opat S, Talaulikar D. Maqbool MG, et al. Among authors: mollee p. Pathology. 2020 Feb;52(2):167-178. doi: 10.1016/j.pathol.2019.11.002. Epub 2020 Jan 3. Pathology. 2020. PMID: 31902622 Review.
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance.
Boyle S, Tobin JWD, Perram J, Hamad N, Gullapalli V, Barraclough A, Singaraveloo L, Han MH, Blennerhassett R, Nelson N, Johnston AM, Talaulikar D, Karpe K, Bhattacharyya A, Cheah CY, Subramoniapillai E, Bokhari W, Lee C, Hawkes EA, Jabbour A, Strasser SI, Chadban SJ, Brown C, Mollee P, Hapgood G. Boyle S, et al. Among authors: mollee p. Hemasphere. 2021 Oct 11;5(11):e648. doi: 10.1097/HS9.0000000000000648. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34651103 Free PMC article.
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.
Creeper K, Augustson B, Kusel K, Fulham MJ, Ho J, Quach H, Mollee P, Weber N, Talaulikar D, Johnston A, Murphy N, Joshua D, Ward C, Ling S, Gibson J, Szer J, Harrison S, Zannettino A, Jaksic W, Lee C, Spencer A, Kalff A, Szabo F, Romeril K, Chan H, Gibbs S, Horvath N, Prince HM. Creeper K, et al. Among authors: mollee p. Intern Med J. 2021 Oct;51(10):1707-1712. doi: 10.1111/imj.15457. Intern Med J. 2021. PMID: 34664367
Bortezomib use and outcomes for the treatment of multiple myeloma.
Loke C, Mollee P, McPherson I, Walpole E, Yue M, Mutsando H, Wong P, Weston H, Tomlinson R, Hollingworth S. Loke C, et al. Among authors: mollee p. Intern Med J. 2020 Sep;50(9):1059-1066. doi: 10.1111/imj.14886. Intern Med J. 2020. PMID: 32369254
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bergin K, et al. Among authors: mollee p. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8. Epub 2021 May 19. Bone Marrow Transplant. 2021. PMID: 34011965
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. McQuilten Z, et al. Among authors: mollee p. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324. Epub 2022 Jul 11. Br J Haematol. 2022. PMID: 35818641 Free PMC article.
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
Sim S, Kalff A, Tuch G, Mollee P, Ho PJ, Harrison S, Gibbs S, Prince HM, Spencer A, Joshua D, Lee C, Ling S, Murphy N, Szabo F, Szer J, Weber N, Ward C, Talaulikar D, Zannettino A, Quach H. Sim S, et al. Among authors: mollee p. Intern Med J. 2023 May;53(5):819-824. doi: 10.1111/imj.16049. Epub 2023 May 10. Intern Med J. 2023. PMID: 36880355 Review.
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Cass SH, et al. Among authors: mollee p. Ann Oncol. 2023 Sep;34(9):796-805. doi: 10.1016/j.annonc.2023.06.007. Epub 2023 Jul 4. Ann Oncol. 2023. PMID: 37414216 Free PMC article.
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, Spencer A. Ho PJ, et al. Among authors: mollee p. Br J Haematol. 2024 Oct;205(4):1337-1345. doi: 10.1111/bjh.19624. Epub 2024 Jul 4. Br J Haematol. 2024. PMID: 38965706
Variation in immunoglobulin use and impact on survival in myeloma.
Chai KL, Wellard C, Thao L, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim K, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso AC, Wong KS, Yoon SS, Spencer A, Wood EM, McQuilten ZK. Chai KL, et al. Among authors: mollee p. EJHaem. 2024 Jun 16;5(4):690-697. doi: 10.1002/jha2.938. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157592 Free PMC article.
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.
Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. Irving A, et al. Among authors: mollee p. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024. PLoS One. 2024. PMID: 39190684 Free PMC article.
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Ho PJ, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010. Epub 2019 May 16. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31208889
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bergin K, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520. doi: 10.1016/j.clml.2021.01.016. Epub 2021 Jan 30. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33785297
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft.
Rees MJ, Mollee P, Ng JY, Murton A, Gonsalves JF, Panigrahi A, Beer H, Loh J, Nguyen P, Hunt S, Jina H, Wayte R, Sutrave G, Tan J, Abeyakoon C, Chee A, Augustson B, Kalro A, Lee C, Agrawal S, Churilov L, Chua CC, Lim ABM, Zantomio D, Grigg A. Rees MJ, et al. Among authors: mollee p. Bone Marrow Transplant. 2021 Sep;56(9):2152-2159. doi: 10.1038/s41409-021-01300-2. Epub 2021 Apr 28. Bone Marrow Transplant. 2021. PMID: 33911199
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald EJ, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, Spencer A; Myeloma and Related Diseases Registry Investigators. Tan JLC, et al. Among authors: mollee p. Br J Haematol. 2023 Jan;200(2):e17-e21. doi: 10.1111/bjh.18536. Epub 2022 Nov 2. Br J Haematol. 2023. PMID: 36321478 No abstract available.
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: mollee p. Haematologica. 2024 Jul 1;109(7):2229-2238. doi: 10.3324/haematol.2023.284238. Haematologica. 2024. PMID: 38235519 Free PMC article. Clinical Trial.
Pomalidomide - Author Reply.
Scott AP, Mollee P. Scott AP, et al. Among authors: mollee p. Leuk Lymphoma. 2019 Apr;60(4):1105. doi: 10.1080/10428194.2018.1516884. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277106 No abstract available.
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
Ho PJ, Spencer A, Mollee P, Bryant CE, Enjeti AK, Horvath N, Butcher BE, Trotman J, Gibbs S, Joshua DE. Ho PJ, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):543-552.e1. doi: 10.1016/j.clml.2024.04.001. Epub 2024 Apr 7. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38702217
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, Saal R, Gill D, Prince HM, Marlton P, Mollee P. Keane C, et al. Among authors: mollee p. Hematol Oncol. 2006 Sep;24(3):159-63. doi: 10.1002/hon.784. Hematol Oncol. 2006. PMID: 16775841
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Miles Prince H, Mollee P, Spencer A, Joy Ho P, Harrison SJ, Lee C, Augustson B, Daly J. Quach H, et al. Among authors: mollee p. Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707. Intern Med J. 2018. PMID: 29415351 Review.
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH. Leung N, et al. Among authors: mollee p. Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Nat Rev Nephrol. 2019. PMID: 30510265 Free PMC article.
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, Mollee P, Hájek R, Moreau P, Jaccard A, Schönland SO, Filshie R, Nicolas-Virelizier E, Augustson B, Mateos MV, Wechalekar A, Hachulla E, Milani P, Dimopoulos MA, Fermand JP, Foli A, Gavriatopoulou M, Klersy C, Palumbo A, Sonneveld P, Johnsen HE, Merlini G, Palladini G. Kastritis E, et al. Among authors: mollee p. J Clin Oncol. 2020 Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730181 Clinical Trial.
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Boyle S, et al. Among authors: mollee p. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677. Epub 2021 Jun 26. Eur J Haematol. 2021. PMID: 34129711 No abstract available.
Promyelocytic transformation of polycythaemia vera (PV).
Mollee PN, Taylor KM, Williams B. Mollee PN, et al. Aust N Z J Med. 1997 Dec;27(6):709-10. doi: 10.1111/j.1445-5994.1997.tb01007.x. Aust N Z J Med. 1997. PMID: 9483243 No abstract available.
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network. Trappe R, et al. Among authors: mollee p. Lancet Oncol. 2012 Feb;13(2):196-206. doi: 10.1016/S1470-2045(11)70300-X. Epub 2011 Dec 13. Lancet Oncol. 2012. PMID: 22173060 Clinical Trial.
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: mollee p. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial.
Rickard CM, Marsh NM, Webster J, Gavin NC, Chan RJ, McCarthy AL, Mollee P, Ullman AJ, Kleidon T, Chopra V, Zhang L, McGrail MR, Larsen E, Choudhury MA, Keogh S, Alexandrou E, McMillan DJ, Mervin MC, Paterson DL, Cooke M, Ray-Barruel G, Castillo MI, Hallahan A, Corley A, Geoffrey Playford E. Rickard CM, et al. Among authors: mollee p. BMJ Open. 2017 Jun 15;7(6):e015291. doi: 10.1136/bmjopen-2016-015291. BMJ Open. 2017. PMID: 28619777 Free PMC article. Clinical Trial.
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU. Zimmermann H, et al. Among authors: mollee p. Transplantation. 2018 Nov;102(11):1914-1923. doi: 10.1097/TP.0000000000002269. Transplantation. 2018. PMID: 29757894
Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH. Leung N, et al. Among authors: mollee p. Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7. Nat Rev Nephrol. 2019. PMID: 30568288 Free PMC article.
Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol.
Ullman AJ, August D, Kleidon T, Walker R, Marsh NM, Bulmer A, Pearch B, Runnegar N, Schults JA, Leema J, Lee-Archer P, Biles C, Southam K, Gibson V, Byrnes J, Ware RS, Chopra V, Coulthard A, Mollee P, Rickard CM, Harris PNA. Ullman AJ, et al. Among authors: mollee p. BMJ Open. 2021 Apr 14;11(4):e042475. doi: 10.1136/bmjopen-2020-042475. BMJ Open. 2021. PMID: 33853797 Free PMC article.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. Among authors: mollee p. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Proteomics in molecular diagnosis: typing of amyloidosis.
Loo D, Mollee PN, Renaut P, Hill MM. Loo D, et al. Among authors: mollee pn. J Biomed Biotechnol. 2011;2011:754109. doi: 10.1155/2011/754109. Epub 2011 Oct 29. J Biomed Biotechnol. 2011. PMID: 22131817 Free PMC article. Review.
Malabsorption Secondary to Gout-Induced Amyloidosis.
Azzam A, Balasubramaniam R, Safa S, McIvor C, Mollee P. Azzam A, et al. Among authors: mollee p. ACG Case Rep J. 2017 Mar 1;4:e32. doi: 10.14309/crj.2017.32. eCollection 2017. ACG Case Rep J. 2017. PMID: 28286797 Free PMC article.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW. Weinkove R, et al. Among authors: mollee p. Med J Aust. 2020 Jun;212(10):481-489. doi: 10.5694/mja2.50607. Epub 2020 May 13. Med J Aust. 2020. PMID: 32401360 Free PMC article.
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Perrot A, et al. Among authors: mollee p. J Clin Oncol. 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. Epub 2020 Dec 16. J Clin Oncol. 2021. PMID: 33326255 Free PMC article. Clinical Trial.
The Clinical Impact of Proteomics in Amyloid Typing.
Hill MM, Dasari S, Mollee P, Merlini G, Costello CE, Hazenberg BPC, Grogan M, Dispenzieri A, Gertz MA, Kourelis T, McPhail ED. Hill MM, et al. Among authors: mollee p. Mayo Clin Proc. 2021 May;96(5):1122-1127. doi: 10.1016/j.mayocp.2020.12.002. Epub 2021 Apr 9. Mayo Clin Proc. 2021. PMID: 33840526 Free PMC article. No abstract available.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Kalff A, et al. Among authors: mollee p. Haematologica. 2022 Jan 1;107(1):321-325. doi: 10.3324/haematol.2021.278655. Haematologica. 2022. PMID: 34587718 Free PMC article. No abstract available.
Paraprotein Sample Exchange in Australia and New Zealand - 2018.
Wijeratne N, Tate JR, Toit SD, Smith JD, Soepnel A, Choy KW, Martin H, Henry R, Glegg K, Byrnes E, Wienholt L, Mollee P. Wijeratne N, et al. Among authors: mollee p. Clin Biochem Rev. 2019 Feb;40(1):43-54. Clin Biochem Rev. 2019. PMID: 30828119 Free PMC article.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD. Sanchorawala V, et al. Among authors: mollee p. Am J Hematol. 2022 Jun 1;97(6):719-730. doi: 10.1002/ajh.26536. Epub 2022 Mar 30. Am J Hematol. 2022. PMID: 35293006 Free article. Clinical Trial.
Current approaches to the diagnosis and management of amyloidosis.
Taylor MS, Sidiqi H, Hare J, Kwok F, Choi B, Lee D, Baumwol J, Carroll AS, Vucic S, Neely P, Korczyk D, Thomas L, Mollee P, Stewart GJ, Gibbs SDJ. Taylor MS, et al. Among authors: mollee p. Intern Med J. 2022 Dec;52(12):2046-2067. doi: 10.1111/imj.15974. Epub 2022 Dec 7. Intern Med J. 2022. PMID: 36478370 Review.
Safety, Feasibility, and Acceptability of a Multisite Individualized Exercise Intervention for People with Multiple Myeloma.
Nicol JL, Cunningham BJ, Woodrow C, Adlard KN, Papinczak ZE, Spence RR, Boytar AN, Mollee P, Weber N, Nicol AJ, Hill MM, Skinner TL. Nicol JL, et al. Among authors: mollee p. Med Sci Sports Exerc. 2023 Dec 1;55(12):2214-2227. doi: 10.1249/MSS.0000000000003267. Epub 2023 Aug 2. Med Sci Sports Exerc. 2023. PMID: 37535331 Clinical Trial.
A Comparison of Peripherally Inserted Central Catheter Materials.
Ullman AJ, August D, Kleidon TM, Walker RM, Marsh N, Bulmer AC, Pearch B, Runnegar N, Leema J, Lee-Archer P, Biles C, Gibson V, Royle R, Southam K, Byrnes J, Chopra V, Coulthard A, Mollee P, Rickard CM, Harris PNA, Ware RS. Ullman AJ, et al. Among authors: mollee p. N Engl J Med. 2025 Jan 9;392(2):161-172. doi: 10.1056/NEJMoa2406815. N Engl J Med. 2025. PMID: 39778170 Clinical Trial.
184 results